[The no-reflow phenomenon and its clinical significance]

Area of Science:

• Cardiology
• Vascular Biology
• Interventional Cardiology

Background:

• The no-reflow phenomenon is inadequate myocardial perfusion without mechanical blockage.
• It complicates coronary interventions like angioplasty and bypass surgery.
• This phenomenon worsens clinical outcomes, increasing heart failure and mortality.

Purpose of the Study:

• To review the pathogenesis of no-reflow.
• To discuss current and potential treatments.
• To highlight the rationale for early preventive drug use.

Main Methods:

• Literature review of no-reflow phenomenon.
• Analysis of contributing factors: endothelial dysfunction, rheology, autoregulation.
• Summary of pharmacological interventions.

Main Results:

• No-reflow involves microvascular dysfunction, not just large vessel occlusion.
• Key pathogenetic factors include endothelial changes, altered blood flow properties, and impaired autoregulation.
• Effective treatments involve intracoronary verapamil, adenosine, and systemic agents like nicorandil and glycoprotein IIb/IIIa inhibitors.

Conclusions:

• No-reflow significantly impacts post-procedural cardiac health.
• Understanding its pathogenesis is crucial for effective management.
• Early preventive strategies using specific drugs are vital for at-risk patients, potentially linking to Syndrome X.